亨迪药业
(301211)
| 流通市值：50.34亿 | | | 总市值：50.34亿 |
| 流通股本：2.88亿 | | | 总股本：2.88亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 494,729,887.37 | 543,139,791.63 | 520,745,020.94 | 1,022,661,699.57 |
| 应收票据及应收账款 | 76,170,984.04 | 69,289,591.32 | 70,402,385.55 | 76,525,420.12 |
| 其中：应收票据 | 10,156,038.96 | 20,662,718.72 | 5,123,748.22 | 5,738,353.36 |
| 应收账款 | 66,014,945.08 | 48,626,872.6 | 65,278,637.33 | 70,787,066.76 |
| 应收款项融资 | 1,846,633.8 | 6,239,157.54 | 2,691,154.3 | 2,975,294.74 |
| 预付款项 | 8,745,233.44 | 3,710,051.72 | 13,238,346.49 | 8,302,060.91 |
| 其他应收款合计 | 4,799,280.14 | 5,153,940.16 | 8,698,567.85 | 4,367,643.54 |
| 存货 | 133,728,313.29 | 137,851,042.47 | 155,087,639.39 | 180,162,422.14 |
| 其他流动资产 | 10,488,478.67 | 15,677,305.39 | 9,159,914.94 | 7,966,289.25 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 1,859,505,802.43 | 1,874,616,455.24 | 1,876,829,237.79 | 1,901,026,904.25 |
| 非流动资产: | | | | |
| 其他权益工具投资 | 9,642,719.95 | 9,642,719.95 | 10,000,000 | 10,000,000 |
| 固定资产 | 465,380,482.46 | 470,091,651.39 | 119,428,946.71 | 123,476,847.87 |
| 在建工程 | 61,467,339.77 | 53,498,889.77 | 350,785,656.54 | 312,049,463.29 |
| 使用权资产 | 3,814,376.28 | 4,161,137.76 | 4,587,185.79 | 4,933,947.27 |
| 无形资产 | 68,410,225.99 | 68,938,485.4 | 69,458,187.73 | 70,020,711.16 |
| 长期待摊费用 | 1,000,614.88 | 1,047,542.23 | 1,118,965.57 | 1,190,388.91 |
| 递延所得税资产 | 2,046,603.36 | 2,046,603.36 | 2,194,552.13 | 2,194,552.13 |
| 其他非流动资产 | 297,478.37 | 4,612,208.91 | 2,666,363.57 | 3,926,637.42 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 612,059,841.06 | 614,039,238.77 | 560,239,858.04 | 527,792,548.05 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 2,471,565,643.49 | 2,488,655,694.01 | 2,437,069,095.83 | 2,428,819,452.3 |
| 流动负债: | | | | |
| 应付票据及应付账款 | 98,888,313.37 | 116,041,734.96 | 88,954,043.01 | 85,195,864.6 |
| 应付账款 | 98,888,313.37 | 116,041,734.96 | 88,954,043.01 | 85,195,864.6 |
| 合同负债 | 9,787,083.32 | 11,872,581.4 | 15,592,445.27 | 9,862,540.52 |
| 应付职工薪酬 | 9,468,307.83 | 12,762,176.07 | 10,064,402.26 | 8,481,020.16 |
| 应交税费 | 4,454,567.73 | 4,780,434.98 | 5,694,402.2 | 13,339,907.19 |
| 其他应付款合计 | 1,890,367.78 | 2,548,482.17 | 1,839,441.19 | 3,250,794.32 |
| 一年内到期的非流动负债 | 1,592,265.12 | 1,592,265.12 | 1,508,198.7 | 1,508,198.7 |
| 其他流动负债 | 9,950,313.56 | 14,786,144.8 | 4,708,468.22 | 5,322,553.36 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 136,031,218.71 | 164,383,819.5 | 128,361,400.85 | 126,960,878.85 |
| 非流动负债: | | | | |
| 租赁负债 | 3,677,629.22 | 3,624,859 | 3,716,346.68 | 4,063,720.56 |
| 递延收益 | 2,030,619.58 | 2,039,732.8 | 2,070,403.02 | 2,079,516.24 |
| 递延所得税负债 | 8,918,749.55 | 8,918,749.55 | 7,492,063.02 | 7,492,063.02 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 14,626,998.35 | 14,583,341.35 | 13,278,812.72 | 13,635,299.82 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 150,658,217.06 | 178,967,160.85 | 141,640,213.57 | 140,596,178.67 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 288,000,000 | 288,000,000 | 288,000,000 | 288,000,000 |
| 资本公积 | 1,756,512,267.22 | 1,756,512,267.22 | 1,756,512,267.22 | 1,756,512,267.22 |
| 其他综合收益 | -303,688.04 | -303,688.04 | - | - |
| 专项储备 | 892,807.92 | - | 2,322,494.56 | 1,282,420.9 |
| 盈余公积 | 57,925,227.06 | 57,925,227.06 | 49,972,124.59 | 49,972,124.59 |
| 未分配利润 | 217,880,812.27 | 207,554,726.92 | 198,621,995.89 | 192,456,460.92 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 2,320,907,426.43 | 2,309,688,533.16 | 2,295,428,882.26 | 2,288,223,273.63 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 2,320,907,426.43 | 2,309,688,533.16 | 2,295,428,882.26 | 2,288,223,273.63 |
| 负债和股东权益合计 | 2,471,565,643.49 | 2,488,655,694.01 | 2,437,069,095.83 | 2,428,819,452.3 |
| 公告日期 | 2025-04-28 | 2025-04-24 | 2024-10-28 | 2024-08-29 |
| 审计意见(境内) | | 标准无保留意见 | | |